Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

KETOCONAZOLE

Form:

5 of 5 products shown

3 general benefit · 2 not a benefit

Other products in the same Health Canada class (D01AC, J02A) — coverage varies; not interchangeable

  • Clotrimazole (Clotrimaderm): general benefit, Not a benefit
  • Miconazole nitrate (Micatin): general benefit
  • Betamethasone dipropionate + clotrimazole (Lotriderm Cream): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Fluconazole (Diflucan P.O.S.): general benefit, Limited Use 235, Limited Use 528, Not a benefit
  • Itraconazole (Sporanox): general benefit, Limited Use 570, Not a benefit

7 more in the class list below

Ketoderm · DIN 02245662 · 2% · Cr

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ketoderm · DIN 02245662 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2004-04-06 Health Canada: Marketed since 2004-03-19 · brand KETODERM CREAM 2% · ATC D01AC08 KETOCONAZOLE · form Cream · route Topical · ingredients KETOCONAZOLE 2 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ketoderm: Formulary list price $0.4043/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4043 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69762 · Verify on the e-Formulary ↗ (DIN 02245662)

Source record
DIN 02245662: Ketoderm Raw flags: sec3=Y Item: 840408034; group id 821; item number 2003; lccId None; manufacturer id TAR Source form: Cr; strength: 2% Recorded listing: General benefit Source prices (unrounded): $0.4043; ministry $0.4043 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245662 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69762
Interchangeable products
Nizoral · DIN 00703974 · not recorded
Shortage status: resolved shortage (ended 2020-05-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245662
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ketoconazole · DIN 02237235 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ketoconazole · DIN 02237235 Manufacturer: Apotex Inc.; listing date 1999-09-15 Daily cost (source): $0.9393 Health Canada: Marketed since 2021-11-08 · brand APO-KETOCONAZOLE · ATC J02AB02 KETOCONAZOLE · form Tablet · route Oral · ingredients KETOCONAZOLE 200 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ketoconazole: Formulary list price $0.9393/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9393 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60554 · Verify on the e-Formulary ↗ (DIN 02237235)

Source record
DIN 02237235: Apo-Ketoconazole Raw flags: sec3=Y Item: 081204010; group id 12; item number 0015; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.9393; ministry $0.9393 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237235 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60554 Therapeutic Notes (formulary) A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.
Interchangeable products
Nizoral · DIN 00633836 · not recorded Teva-Ketoconazole · DIN 02231061 · $0.9393
Shortage status: resolved shortage (ended 2020-08-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237235
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Ketoconazole · DIN 02231061 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ketoconazole · DIN 02231061 Manufacturer: Teva Canada Limited; listing date 2000-01-17 Daily cost (source): $0.9393 Health Canada: Marketed since 2014-03-29 · brand TEVA-KETOCONAZOLE · ATC J02AB02 KETOCONAZOLE · form Tablet · route Oral · ingredients KETOCONAZOLE 200 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ketoconazole: Formulary list price $0.9393/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9393 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50343 · Verify on the e-Formulary ↗ (DIN 02231061)

Source record
DIN 02231061: Teva-Ketoconazole Raw flags: sec3=Y Item: 081204010; group id 12; item number 0015; lccId None; manufacturer id TEV Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.9393; ministry $0.9393 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231061 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50343 Therapeutic Notes (formulary) A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.
Interchangeable products
Apo-Ketoconazole · DIN 02237235 · $0.9393 Nizoral · DIN 00633836 · not recorded
Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231061
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nizoral · DIN 00703974 · 2% · Cr

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.Discontinued 2007-08-02 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nizoral · DIN 00703974 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-08-02 · brand NIZORAL CREAM 2% · ATC D01AC08 KETOCONAZOLE · form Cream · route Topical · ingredients KETOCONAZOLE 2 % · company Mcneil consumer healthcare division of johnson & johnson inc · schedule Prescription
Check this DIN again · Health Canada product record

Nizoral: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8378 · Verify on the e-Formulary ↗ (DIN 00703974)

Source record
DIN 00703974: Nizoral Raw flags: notABenefit=Y, sec3=Y Item: 840408034; group id 821; item number 2003; lccId None; manufacturer id JAN Source form: Cr; strength: 2% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00703974 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8378
Interchangeable products
Ketoderm · DIN 02245662 · $0.4043
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00703974
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.

Nizoral · DIN 00633836 · 200mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-02-06 — choose a marketed DIN from the same-category list.Discontinued 2003-02-06 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-02-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-02-06 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nizoral · DIN 00633836 Manufacturer: Janssen Inc.; listing date 1996-10-01 Daily cost (source): $0.9393 Health Canada: Cancelled post market since 2003-02-06 · brand NIZORAL TABLETS 200MG · ATC J02AB02 KETOCONAZOLE · form Tablet · route Oral · ingredients KETOCONAZOLE 200 MG · company Mcneil consumer healthcare division of johnson & johnson inc · schedule Prescription
Check this DIN again · Health Canada product record

Nizoral: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6104 · Verify on the e-Formulary ↗ (DIN 00633836)

Source record
DIN 00633836: Nizoral Raw flags: notABenefit=Y, sec3=Y Item: 081204010; group id 12; item number 0015; lccId None; manufacturer id JAN Source form: Tab; strength: 200mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00633836 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6104 Therapeutic Notes (formulary) A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.
Interchangeable products
Apo-Ketoconazole · DIN 02237235 · $0.9393 Teva-Ketoconazole · DIN 02231061 · $0.9393
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00633836
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-02-06 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, ITRACONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit (14) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles

Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

FLUCONAZOLE

· 8 products · Limited Use, codes 235 · strengths: 150mg · Cap

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS For the treatment of serious or life-threatening systemic fungal infections in normal, predisposed or immunocompromised patients where alternate therapy is considered inappropriate or has been unsuccessful: systemic candidiasis, chronic mucocutaneous candidiasis, coccidioidomycosis and paracoccidioidomycosis, histoplasmosis and chromomycosis. Its use may also be considered in the treatment of severe, recalcitrant dermatophytoses unresponsive to other forms of therapy. The type of organism responsible for the infection should be identified; however, therapy may be initiated prior to obtaining these results, when clinically warranted. 1 Note: The treatment of fungal infections of the CNS is not recommended; ketoconazole penetrates poorly into the CNS. https://pdf.hres.ca/dpd_pm/00024529.PDF PM date: not printed or not captured Source product: TEVA-KETOCONAZOLE; DIN 02231061; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Ketoconazole · DIN 02231061 Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231061

Check this DIN again

Other review policies

For Nizoral: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026